Form 4: Pelthos Director Pauls Gifts Shares to Trust

Pelthos Therapeutics Inc. Director Matthew Pauls reported the vesting of restricted stock units and a gift of 9,542 common shares to a trust.

Summary

• Matthew Pauls, a Director of Pelthos Therapeutics Inc. (PTHS), reported several transactions involving the company's common stock and restricted stock units (RSUs).
• On July 2, 2025, 8,493 shares of common stock were acquired upon the vesting of RSUs, bringing his direct beneficial ownership to 8,493 shares.
• On October 2, 2025, an additional 2,123 shares of common stock were acquired through RSU vesting, increasing his direct beneficial ownership to 10,616 shares.
• On December 10, 2025, Pauls transferred 9,542 shares of common stock to the GP 2024 Trust for no consideration, reducing his direct beneficial ownership to 1,074 shares.
• The RSU grant on July 2, 2025, totaled 25,478 units, with one-third vesting immediately and the remainder vesting quarterly over two years.
• Following the gift, Pauls disclaims beneficial ownership of the shares held by the Trust, retaining only any pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine RSU vestings and a personal estate planning transaction (gift to a trust) by a director. It does not contain information that would significantly alter the company's operational or financial outlook.

Positives

• Continued vesting of Restricted Stock Units (RSUs) indicates ongoing compensation and retention of a key director.
• The initial grant of 25,478 RSUs on July 2, 2025, demonstrates a significant equity award to a director.

Negatives

• A significant portion of directly held common stock (9,542 shares) was transferred out of the director's direct beneficial ownership via a gift.
• The director disclaims beneficial ownership of the gifted shares, reducing his direct stake and control over those shares.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This filing details an insider transaction, specifically the vesting of equity compensation and a personal estate planning gift by a director. It does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• Transfer of 9,542 shares of Common Stock to GP 2024 Trust, U/A Dated, 12/20/2024, for no consideration. The reporting person disclaims beneficial ownership of these shares, but the transaction is with a related entity.

Stakeholder Impact

• Shareholders: The gift of shares to a trust by a director slightly reduces the director's direct beneficial ownership, which could be seen as a minor reduction in direct alignment, though the shares remain within a related entity. The vesting of RSUs increases the director's direct ownership, aligning interests.

Next Steps

• Remaining RSUs will continue to vest in equal installments on a quarterly basis over a period of two years from the initial grant date of July 2, 2025.

Key Dates

Recommendation

This Form 4 filing details routine RSU vestings and a personal estate planning transaction by a director. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The director's overall equity exposure, including RSUs and shares held by the trust, remains substantial, indicating continued alignment with shareholder interests.

Keywords

Pelthos Therapeutics, PTHS, Matthew Pauls, Form 4, Insider Trading, Restricted Stock Units, RSU, Common Stock, Share Gift, Director Ownership, Equity Compensation, Beneficial Ownership